ClinicalTrials.gg
RecruitingNCT06907810LICPUpdated Apr 2, 2025

Study of Lipid Mediators in Chronic Postoperative Pain - LICP

An interventional study of Blood sample + questionnaire in Breast Cancer Female and Postoperative Pain, sponsored by Université Catholique de Louvain. Recruiting at 1 site in Belgium. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-02.

Sponsored by Université Catholique de Louvain · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 72 studies in Pain, Postoperative with a site in Belgium — 12 open to participants now, 15 under way, none of them phase 3. Pain, Postoperative · Belgium.

Planned enrollment
7th of 55
300 · median 70
Started
2025
with 4 others
No phase
34 of 72
7 open now
Primary completion
2027-03
later than 6 of 14 live
Registered
61st of 72
by date
Lead sponsor
4 of 72
Université Catholique de Louvain

Among the 72 studies in Pain, Postoperative with a site in Belgium, this one is the 7th largest by planned enrollment of the 55 interventional ones that give a count, is one of 5 that started in 2025, is one of 34 with no phase, reaches primary completion later than 6 of the 14 other live ones, and was the 61st registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

12 of the 72 studies in Pain, Postoperative with a site in Belgium are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Pain, Postoperative with a site in Belgium, or all of them as a file.
02

Study summary

This interventional prospective study aims firstly to investigate variations in lipid levels in blood samples and their potential relationship with the duration and/or intensity of post-operative pain. Secondly, it aims to investigate the activation of peripheral blood mononuclear cells and neutrophils in patient blood samples. The study will enrol women aged 18 years or older who have been newly diagnosed with primary invasive or non-invasive breast cancer requiring surgical removal of the tumour, with or without axillary surgery.

The main objectives of the study are To assess whether there is an association between circulating levels of lipid mediators and chronicity (> 3 months) of postoperative pain after breast cancer surgery.

To assess whether circulating levels of lipid mediators can predict chronicity of postoperative pain in breast cancer surgery.

To assess the existence of an association between resected tissue levels of lipid mediators and chronicity of postoperative pain in breast cancer surgery.

To assess whether tissue levels of lipid mediators can predict chronicity of postoperative pain in breast cancer surgery.

03

Conditions studied

  • Breast Cancer Female
  • Postoperative Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women older than 18 years
  • Newly diagnosed primary invasive or non-invasive breast cancer, requiring surgical excision of the tumor, with or without axillary surgery
  • Able to give

Exclusion criteria

Exclusion Criteria:

  • Men
  • Women aged less than 18 years
  • Pregnant women
  • History of major psychiatric disorders
  • Previous breast or axillary surgery, recurrent disease or detectable disease at the time of diagnosis
  • Unable to give
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Chronic pain

    Other: Blood sample + questionnaire

  • Active comparator
    No chronic pain

    Other: Blood sample + questionnaire

Interventions

  • OtherBlood sample + questionnaire

    * blood sample before tumor surgery and at every follow-up visit * questionnaire before tumor surgery and at every follow-up visit

06

What researchers measure

Primary outcomes

  1. Pain intensity

    Pain intensity will be evaluated using a standardized questionnaire completed by participants at each medical consultation.

    Time frame: Throughout the study, an average of 2 years

  2. Pain duration

    Pain duration will be evaluated using a standardized questionnaire completed by participants at each medical consultation.

    Time frame: Throughout the study, an average of 2 years

  3. Lipid Mediator Levels in Blood

    Lipid mediator levels will be quantified in blood samples by LC-MS methods

    Time frame: Throughout the study, an average of 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Mar 2027, 24 months after the start.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 24 months is above that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2025
First posted
Apr 2, 2025
StartActual
Mar 12, 2025
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Apr 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06907810
Responsible party
Sponsor
First posted
Apr 2, 2025
Start date
Mar 12, 2025
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Apr 2, 2025

Study contacts

Martine Berlière, MD, PhD
Contact
martine.berliere@saintluc.uclouvain.be
00327641075
Lisa Martin, MSC
Contact
lisa.martin@uclouvain.be
Mireille Alhouayek, PhD
principal investigator · Université Catholique de Louvain

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion